AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29456025 — intervention group
Group type: COMPARATOR
Intervention: Control (weekly e-mail newsletter)
Number of subjects: 128
Study 27088240 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class policy reading and discussion
Number of subjects: 1195
Study 27088240 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class policy reading
Number of subjects: 1195
Study 27088240 — intervention group
Group type: COMPARATOR
Intervention: No reading or discussion
Number of subjects: 1195
Study 24812891 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuanxiong Aerosol (KA), sublingual spray 0.6 mL three times during angina attack
Number of subjects: 780
Study 24812891 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin Tablet (NT), 0.5 mg sublingually dissolved during angina attack
Number of subjects: 780
Study 24812891 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuanxiong Aerosol (KA)
Number of subjects: 780
Study 24812891 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin Tablet (NT)
Number of subjects: 780
Study 23654012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency pulsing electromagnetic field (LFEMF)
Number of subjects: 60
Study 23654012 — intervention group
Group type: COMPARATOR
Intervention: Interference currents (IFC)
Number of subjects: 60
Study 23654012 — intervention group
Group type: COMPARATOR
Intervention: Medicamentous therapy (Diklofenak 100 mg, 2 tablets per day)
Number of subjects: 60
Study 20484064 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) with 10 minutes of lower limb ischemia-reperfusion
Number of subjects: 70
Study 20484064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 70
Study 20484064 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 70
Study 18797179 — intervention group
Group type: EXPERIMENTAL
Intervention: AIC immunotherapy (6 escalating doses of AIC 0.06-12 microg; n = 12)
Number of subjects: 19
Study 18797179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 19
Study 15723704 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable pins
Number of subjects: 54
Study 15723704 — intervention group
Group type: COMPARATOR
Intervention: Resorbable screws
Number of subjects: 54
Study 12486484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 45
Study 12486484 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 45
Study 10068011 — intervention group
Group type: EXPERIMENTAL
Intervention: Colles'‐type plaster cast with the wrist immobilised in 20 degrees flexion
Number of subjects: 0
Study 10068011 — intervention group
Group type: COMPARATOR
Intervention: Colles'‐type plaster cast with the wrist immobilised in 20 degrees extension
Number of subjects: 0
Study 8635184 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of tolcapone
Number of subjects: 10
Study 8635184 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of tolcapone
Number of subjects: 10
Study 8635184 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 2169213 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU.kg‐1.day‐1 heparin (group HEP)
Number of subjects: 0
Study 2169213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg.kg‐1.day‐1 enoxaparin (group ENX)
Number of subjects: 0
Study 2169213 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg.kg‐1.day‐1 enoxaparin with 5 ng.kg‐1.min‐1 prostaglandin I2 (group ENX and PGI2)
Number of subjects: 0
Study 6901189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with no added sugar for 3 months
Number of subjects: 40
Study 6901189 — intervention group
Group type: COMPARATOR
Intervention: Regular baby food with additional sugar for 3 months
Number of subjects: 40
Study 30991255 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 86
Study 30991255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 27444991 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous saline bladder irrigation (CSBI) at 2000 mL/h for the first 1 hour, then 1000 mL/h for 2 hours, followed by 500 mL/h for 15 hours
Number of subjects: 250
Study 27444991 — intervention group
Group type: COMPARATOR
Intervention: Single immediate instillation of mitomycin C (MMC)
Number of subjects: 250
Study 27444991 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous saline bladder irrigation (CSBI)
Number of subjects: 250
Study 27444991 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 250
Study 25976647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 20 mg per day lutein (L), 0.86 mg per day zeaxanthin (Z); Ultra Lutein
Number of subjects: 67
Study 25976647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 10 mg per day meso-zeaxanthin (MZ), 10 mg per day L, 2 mg per day Z; Macushield; Macuhealth
Number of subjects: 67
Study 25976647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 17 mg per day MZ, 3 mg per day L, 2 mg per day Z
Number of subjects: 67
Study 23328337 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac
Number of subjects: 277
Study 23328337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 277
Study 23328337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 20722060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic patients with IPAA
Number of subjects: 36
Study 20722060 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic white patients with IPAA
Number of subjects: 36
Study 19832788 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 minutes of moderate intensity stationary cycling
Number of subjects: 20
Study 19832788 — intervention group
Group type: COMPARATOR
Intervention: Passive seating (control)
Number of subjects: 20
Study 17083064 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (520 mg/d)
Number of subjects: 24
Study 17083064 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg/d)
Number of subjects: 24
Study 12950422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 22
Study 12950422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10977396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with the 23‐valent pneumococcal polysaccharide vaccine
Number of subjects: 1000
Study 10977396 — intervention group
Group type: COMPARATOR
Intervention: No vaccination and treatment
Number of subjects: 1000
Study 8783051 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total
Number of subjects: 0
Study 8783051 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest regular
Number of subjects: 0
Study 8783051 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Tartar
Number of subjects: 0
Study 8783051 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate regular
Number of subjects: 0
Study 8783051 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 0-6 gel
Number of subjects: 0
Study 8783051 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 1731288 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine weekly cervical examinations at term (from 37 weeks until delivery)
Number of subjects: 604
Study 1731288 — intervention group
Group type: COMPARATOR
Intervention: No examination group (routine examinations not performed)
Number of subjects: 604
Study 1731288 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine weekly cervical examinations at term
Number of subjects: 604
Study 1731288 — intervention group
Group type: COMPARATOR
Intervention: No examination group
Number of subjects: 604
Study 2864891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium alone (160 micrograms)
Number of subjects: 10
Study 2864891 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol alone (400 micrograms) after placebo
Number of subjects: 10
Study 2864891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium with fenoterol
Number of subjects: 10
Study 30565892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU monthly)
Number of subjects: 217
Study 30565892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 30180683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vowel stimuli with low broadband error, high vowel diversity, and high vowel discriminability.
Number of subjects: 0
Study 30180683 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusable vowels that were most susceptible to filtering.
Number of subjects: 0
Study 30180683 — intervention group
Group type: EXPERIMENTAL
Intervention: Least susceptible vowels.
Number of subjects: 0
Study 26757045 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT depot extract (0.0625-0.75 SPT units)
Number of subjects: 136
Study 26757045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 25239216 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (maltodextrin solution)
Number of subjects: 24
Study 25239216 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group (placebo solution)
Number of subjects: 24
Study 22873191 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in learning about 12-Step groups
Number of subjects: 6
Study 22873191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' perception of the helpfulness of 12-Step groups
Number of subjects: 6
Study 22873191 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of patients' problems with substance abuse
Number of subjects: 6
Study 22873191 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic and experiential education for clinicians in substance abuse and mutual aid
Number of subjects: 6
Study 20157677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond Plus (SB)
Number of subjects: 0
Study 20157677 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 0
Study 20157677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt (AP)
Number of subjects: 0
Study 20157677 — intervention group
Group type: COMPARATOR
Intervention: Preparation walls (pulpal, axial, gingival)
Number of subjects: 0
Study 17306498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular immunotherapies
Number of subjects: 0
Study 17306498 — intervention group
Group type: COMPARATOR
Intervention: New agents for treating castration-resistant prostate cancer
Number of subjects: 0
Study 15674305 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 84
Study 15674305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol supplementation
Number of subjects: 84
Study 15674305 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 11879139 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical unoprostone
Number of subjects: 24
Study 11879139 — intervention group
Group type: COMPARATOR
Intervention: ET-1 administration
Number of subjects: 24
Study 10673968 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient treatment preferences
Number of subjects: 0
Study 10673968 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0
Study 8822422 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 32489 (Puregon)
Number of subjects: 99
Study 8822422 — intervention group
Group type: COMPARATOR
Intervention: Urinary FSH (Metrodin)
Number of subjects: 99
Study 2138477 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Adriamycin i.v. weekly (Awkly)
Number of subjects: 166
Study 2138477 — intervention group
Group type: COMPARATOR
Intervention: 50 mg 4‐epidoxorubicin biweekly (EPIbiwkly)
Number of subjects: 166
Study 6766411 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate infusions (62 ± 5 mmol sodium phosphate)
Number of subjects: 40
Study 6766411 — intervention group
Group type: COMPARATOR
Intervention: Standardized conventional treatment alone
Number of subjects: 40
Study 31860326 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 149
Study 31860326 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 149
Study 29974963 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg administered subcutaneously every 4 weeks for 12 weeks
Number of subjects: 30
Study 28327692 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-extractive implants
Number of subjects: 210
Study 28327692 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-delayed implants at 6 weeks
Number of subjects: 210
Study 28327692 — intervention group
Group type: COMPARATOR
Intervention: Delayed implants after 4 months
Number of subjects: 210
Study 28327692 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 210
Study 25821849 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fluoride dentifrice (5000 µg F/g)
Number of subjects: 12
Study 25821849 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride dentifrice (1100 µg F/g)
Number of subjects: 12
Study 23543359 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 253
Study 23543359 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic services (Control)
Number of subjects: 253
Study 23543359 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention (dose-response analysis)
Number of subjects: 253
Study 22575317 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest heart rate tertile
Number of subjects: 0
Study 22575317 — intervention group
Group type: COMPARATOR
Intervention: Lowest heart rate tertile
Number of subjects: 0
Study 22575317 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AF at baseline
Number of subjects: 0
Study 19848209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanqidan Granules (SQD)
Number of subjects: 45
Study 19848209 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic drugs (glipizide, pioglitazone, metformin) and antihypertensive drug (nifedipine)
Number of subjects: 45
Study 17489878 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg telmisartan/day
Number of subjects: 188
Study 17489878 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan/day
Number of subjects: 188
Study 17489878 — intervention group
Group type: COMPARATOR
Intervention: Both telmisartan and irbesartan
Number of subjects: 188
Study 17489878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin (FPI)
Number of subjects: 188
Study 15145107 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training (CT) for 8 weeks
Number of subjects: 19
Study 15145107 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 19
Study 15145107 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training (CT)
Number of subjects: 19
Study 11506246 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (oral prednisone 1.0 mg/Kg/day for 2 months, tapered by 0.2 mg/Kg/day every month) plus ramipril (2.5 mg/day for one month, increased by 1.25 mg/day every month)
Number of subjects: 134
Study 11506246 — intervention group
Group type: COMPARATOR
Intervention: Ramipril alone
Number of subjects: 134
Study 11506246 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids plus ramipril
Number of subjects: 134
Study 9754987 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg alone
Number of subjects: 15
Study 9754987 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg alone
Number of subjects: 15
Study 9754987 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg with zolpidem
Number of subjects: 15
Study 9754987 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg with caffeine 250 mg
Number of subjects: 15
Study 9754987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8116706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin (1 million units of benzylpenicillin intravenously every 4 hours followed by 250 mg of potassium phenoxymethyl penicillin orally twice daily)
Number of subjects: 0
Study 8116706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1968124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 193
Study 146511 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (0.4 g daily)
Number of subjects: 91
Study 146511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 30057283 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐IIV4
Number of subjects: 2247
Study 30057283 — intervention group
Group type: COMPARATOR
Intervention: C‐IIV4
Number of subjects: 2247
Study 29133833 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with isoflavones (SPI)
Number of subjects: 200
Study 29133833 — intervention group
Group type: COMPARATOR
Intervention: Soy protein alone without isoflavones (SP)
Number of subjects: 200
Study 25560477 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI) pain subscale
Number of subjects: 0
Study 25560477 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale (NPRS)
Number of subjects: 0
Study 25560477 — intervention group
Group type: EXPERIMENTAL
Intervention: SPADI
Number of subjects: 0
Study 23644090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (rosuvastatin 40 mg daily)
Number of subjects: 87
Study 23644090 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care lipid-lowering therapy
Number of subjects: 87
Study 21325901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine 12.5 mg (M1)
Number of subjects: 72
Study 21325901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine 25 mg (M2)
Number of subjects: 72
Study 21325901 — intervention group
Group type: COMPARATOR
Intervention: Control group (M0) with bupivacaine 0.5% (10 mg)
Number of subjects: 72
Study 21325901 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of meperidine (M1 and M2)
Number of subjects: 72
Study 19255395 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster seat education and distribution program
Number of subjects: 1010
Study 17077234 — intervention group
Group type: COMPARATOR
Intervention: 25 microg misoprostol vaginal insert
Number of subjects: 124
Study 17077234 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol vaginal insert
Number of subjects: 124
Study 17077234 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg misoprostol vaginal insert
Number of subjects: 124
Study 17077234 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol vaginal insert
Number of subjects: 124
Study 16433203 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-shot allergy vaccine (Pollinex Quattro) containing appropriate allergoids (grass/rye and/or mugwort) adsorbed to L-tyrosine plus a Th1 adjuvant, monophosphoryl lipid A (MPL)
Number of subjects: 21
Study 16433203 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-shot allergy vaccine (Pollinex Quattro)
Number of subjects: 21
Study 16433203 — intervention group
Group type: COMPARATOR
Intervention: Control challenges (similar pollen vaccine without MPL and a tree pollen vaccine with and without MPL)
Number of subjects: 21
Study 12877821 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg twice daily in addition to beclomethasone 500 microg twice daily
Number of subjects: 203
Study 12877821 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone 1000 microg twice daily and placebo
Number of subjects: 203
Study 9950912 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc (6 mg/m2)
Number of subjects: 24
Study 9950912 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (2 ng/kg)
Number of subjects: 24
Study 9950912 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfusion of TNFR:Fc with endotoxin
Number of subjects: 24
Study 9950912 — intervention group
Group type: COMPARATOR
Intervention: Control study day
Number of subjects: 24
Study 8525409 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% neem oil mixed in coconut oil
Number of subjects: 0
Study 2098504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine (LND) in association with radiotherapy
Number of subjects: 60
Study 2098504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine (LND) in association with Lomustine (CCNU)
Number of subjects: 60
Study 7191674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold room environment (temperature 18.9 C or below)
Number of subjects: 42
Study 7191674 — intervention group
Group type: COMPARATOR
Intervention: Warm room environment (temperature 22.2 C or above)
Number of subjects: 42
Study 12377647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 474
Study 12377647 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 474
Study 30199447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minutes of moderate-intensity RW (cycling at 60% of V[Combining Dot Above]O2max)
Number of subjects: 11
Study 30199447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minutes of low-intensity RW (cycling at 30% of V[Combining Dot Above]O2max)
Number of subjects: 11
Study 30199447 — intervention group
Group type: COMPARATOR
Intervention: 15 minutes of seated rest (control)
Number of subjects: 11
Study 26115589 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte gels (0.7±0.1gkg(‐1) BM)
Number of subjects: 8
Study 26115589 — intervention group
Group type: COMPARATOR
Intervention: Energy-free placebo gels
Number of subjects: 8
Study 25310201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50, 70, 100, 150, 200, and 250 mg daily for 5 days
Number of subjects: 31
Study 25310201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25310201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 31
Study 22107609 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (60 mJ/pulse, 10 pps, 60 sec)
Number of subjects: 3
Study 22107609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (60 mJ/pulse, 10 pps, 60 sec)
Number of subjects: 3
Study 22107609 — intervention group
Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 3